Vascular Financial Statements From 2010 to 2024

VBLTDelisted Stock  USD 0.28  0.01  3.45%   
Vascular Biogenics financial statements provide useful quarterly and yearly information to potential Vascular Biogenics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vascular Biogenics financial statements helps investors assess Vascular Biogenics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vascular Biogenics' valuation are summarized below:
Vascular Biogenics does not presently have any fundamental trend indicators for analysis.
Check Vascular Biogenics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vascular Biogenics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Vascular financial statements analysis is a perfect complement when working with Vascular Biogenics Valuation or Volatility modules.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Vascular Biogenics Company Return On Equity Analysis

Vascular Biogenics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity


Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Vascular Biogenics Return On Equity

Most of Vascular Biogenics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vascular Biogenics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Based on the latest financial disclosure, Vascular Biogenics has a Return On Equity of -0.5952. This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

Vascular Biogenics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Vascular Biogenics's current stock value. Our valuation model uses many indicators to compare Vascular Biogenics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vascular Biogenics competition to find correlations between indicators driving Vascular Biogenics's intrinsic value. More Info.
Vascular Biogenics is rated fourth in return on equity category among its peers. It is rated fifth in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Vascular Biogenics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About Vascular Biogenics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Vascular Biogenics income statement, its balance sheet, and the statement of cash flows. Vascular Biogenics investors use historical funamental indicators, such as Vascular Biogenics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Vascular Biogenics investors may use each financial statement separately, they are all related. The changes in Vascular Biogenics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Vascular Biogenics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Vascular Biogenics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Vascular Biogenics. Please read more on our technical analysis and fundamental analysis pages.
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.

Pair Trading with Vascular Biogenics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vascular Biogenics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vascular Biogenics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Vascular Stock

  0.75MCHB Mechanics BankPairCorr

Moving against Vascular Stock

  0.89ALLR Allarity TherapeuticsPairCorr
  0.87INTC Intel Financial Report 25th of July 2024 PairCorr
  0.81MCD McDonalds Financial Report 25th of July 2024 PairCorr
  0.71IBM International Business Financial Report 17th of July 2024 PairCorr
  0.68COCXF Chocoladefabriken LindtPairCorr
The ability to find closely correlated positions to Vascular Biogenics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vascular Biogenics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vascular Biogenics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vascular Biogenics to buy it.
The correlation of Vascular Biogenics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vascular Biogenics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vascular Biogenics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vascular Biogenics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Consideration for investing in Vascular Stock

If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Find actively traded Exchange Traded Funds (ETF) from around the world
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance